Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02037373 · ClinicalTrials.gov registry record
Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation
A clinical trial, sponsored by Octapharma.
- Terminated
- Registry status
- 43
- Enrollment target
NCT02037373 is a clinical trial that was terminated before completion, run by Octapharma. The registered enrollment target is 43 participants.
The verdict
NCT02037373 was terminated before completion, sponsored by Octapharma.
- TERMINATED
- Registry status
- 43 participants
- Enrollment target
Study Summary
Post-Marketing Requirement study to evaluate the safety of octaplas™ versus plasma in patients undergoing orthotopic liver transplantation (OLT). The primary objective is to assess the incidence of hyperfibrinolysis in patients undergoing (OLT) receiving octaplas™ versus regular plasma (e.g., fresh frozen plasma and other FDA and AABB approved plasma products).
Interventions
- BIOLOGICAL Octaplas™
- BIOLOGICAL Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02037373
The ClinicalTrials.gov registry entry for NCT02037373 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Octaplas™ is the first listed.
NCT02037373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02037373 about?
NCT02037373 is a clinical study titled "Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation". Post-Marketing Requirement study to evaluate the safety of octaplas™ versus plasma in patients undergoing orthotopic liver transplantation (OLT). The primary objective is to assess the incidence of hyperfibrinolysis in patients undergoing (OLT) receiving octaplas™ versus regular plasma (e.g., fresh ...
What is the current status of trial NCT02037373?
This trial is currently terminated. The enrollment target is 43 participants. The study started on 2015-08. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02037373?
The interventions under investigation include: Octaplas™ (BIOLOGICAL), Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT02037373?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.